Maria J. Fita-Juan
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanoma.
Journal: Melanoma research
Published: May 11, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.
Journal: European urology open science
Published: March 12, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).
Journal: Frontiers in immunology
Published: February 05, 2026
Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.
Journal: BMC cancer
Published: July 29, 2025
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study.
Journal: European urology oncology
Published: July 07, 2025
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.
Journal: Clinical genitourinary cancer
Published: April 24, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.
Journal: European urology focus
Published: March 08, 2025
Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.
Journal: Future oncology (London, England)
Published: March 03, 2025
Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification.
Journal: Clinical genitourinary cancer
Published: December 20, 2024
Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients.
Journal: Actas urologicas espanolas
Published: November 21, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.
Journal: European urology open science
Published: October 01, 2024
Last Updated: 09/26/2026